Sorrento Therapeutics, Inc. · OTC:SRNE
Sorrento Therapeutics — Investor Presentation (June 2019)
25 slides from Sorrento Therapeutics's investor presentation, Jun 20, 2019
Slide 1: A Leading Immunotherapy and Non-Opioid Pain Management Company
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved A Leading Immunotherapy and Non - Opioid Pain Management Company June 2019 SRNE (NASDAQ)
Slide 2: Disclaimer
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved 2 Disclaimer Certain statements contained in this presentation or in other documents of Sorrento Therapeutics, Inc . (the “Company” or “Sorrento”) and of any of its affiliates, along with certain statements that may be made by management of the
Slide 3: Therapeutic Focus
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved SRNE (NASDAQ) Therapeutic Focus Immuno - Oncology Pain Management (Non - Opioid) 3
Slide 4: Our Four Flagship Programs
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Our Four Flagship Programs RTX (resiniferatoxin) ZTlido ® (lidocaine topical system) 1.8% Commercially available (PHN indication) CD38 Immunotherapies CEA CAR - T Multiple Myeloma CAR - T Phase 1 enrolling DAR - T Target IND filing H2 2019 ADC T
Slide 5: ZTlido (FDA approved) Lidocaine Patch Market Overview
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved US FDA APPROVAL 02/28/18 5 Scilex – ZTlido ® (FDA approved) Lidocaine Patch Market Overview >3 million prescriptions per year More than 120 million prescription lidocaine patches were sold in the US in 2017 according to IMS Benefits vs. other li
Slide 6: ZTlido: Head-to-Head Adhesion Study
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved 6 1 Data from a 12 patient 12 - hour study Adhesion Scores Over Time (Lower Score Demonstrates Better Adhesion) The recommended scoring system for adhesion of transdermal patches are indicated as follows: 0 = ≥ 90% adhered (essentially no lift o
Slide 7: SP-102 Product Features
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Well - tolerated. Key viscous excipient, long history of use including safety and safer repeat injections ᪵ ᪵ Fast acting onset of effect with less spread SP - 102 Product Features ᪵ Potent non - particulate steroid (injectable dexamethasone sod
Slide 8: RTX: A novel therapeutic approach to pain
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved RTX: A novel therapeutic approach to pain Novel mode of action, new therapeutic class of drugs Ultrapotent, highly specific toxin that selectively ablates neurons responsible for afferent signaling (action at the ‘hard wiring’ level) Single inje
Slide 9: A novel therapeutic approach to Osteoarthritis of the Knee Pain
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved 9 Phase 1b double - blinded, placebo controlled study to assess the safety and preliminary efficacy of intra - articular administration of resiniferatoxin or saline control (as placebo group) for the treatment of moderate to severe pain due to o
Slide 10: RTX OA Knee Pain Phase 1b Trial Update: Safety outcomes
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved RTX OA Knee Pain Phase 1b Trial Update Safety outcomes (45 Patients. 37 RTX treated. 8 Control) Cohorts RTX Dose (ug) Subjects Progress Blinding Safety 1 5 ug 6 Complete Unblinded No DLT’s 2 12.5 ug 6 Complete Unblinded No DLT’s 3 20 ug 6 Comple
Slide 11: RTX OA Knee Pain Phase 1b Trial Update: Efficacy outcomes
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Difference of treatment effect - dose groups relative to control (pooled placebo group) Mean WOMAC A1 Pain Score & Standard deviation 11 RTX OA Knee Pain Phase 1b Trial Update Efficacy outcomes (all dose cohorts relative to control) Dose cohort
Slide 12: RTX Phase 1b: Efficacy outcomes (pivotal dose candidates)
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Difference of treatment effect (pivotal dose candidates) relative to control (pooled placebo) Patients with more than 50% reduction in reported pain scores 12 RTX OA Knee Pain Phase 1b Trial Update Efficacy outcomes (pivotal dose candidates rela
Slide 13: RTX Phase 1b: Efficacy beyond study end-point D84
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved RTX OA Knee Pain Phase 1b Trial Update Efficacy outcomes (some patients beyond study end - point D84) Patients with D168 extended follow - up WOMAC A1 Pain Score 13 Five patients were followed to D168 (protocol trial end - point at D84). These p
Slide 14: Additional cohorts being considered prior to pivotal studies
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved RTX OA Knee Pain Phase 1b Trial Update Additional cohorts being considered prior to pivotal studies 14 Sedation & Local Analgesia Administration protocols at 12.5 ug dose (in progress) Limited pre - administration opioids with local supportive n
Slide 15: Upcoming RTX Milestones
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Upcoming RTX Milestones (by Indication and Target Dates) Osteoarthritis Knee Pain Phase 1b to conclude in 2019 Two Phase 3 pivotal trials to start in 1 st half 2020 (USA and Asia - Pacific) Support Phase 2 trials in planning, for implementation
Slide 16: Anti-CEA CAR-T Clinical Experience
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Before Infusion Post - Infusion HITM - SURE Phase 1/2: Clinical Summary Anti - CEA CAR - T Clinical Experience 16 Pre - enrollment history Liver metastases of colon or pancreatic cancer Failed 3 lines of conventional chemotherapy and ablation Pr
Slide 17: CD38 Therapeutics Business Unit - Immunotherapy Pipeline
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved CD38 Therapeutics Business Unit - Immunotherapy Pipeline 17 Program Research IND - Enabling Projected IND Phase 1 CAR - T (autologous) ADC DAR - T (allogeneic) CD38/CD3 BsAb H2 2019 H2 2019 H1 2020 CD38 CAR - T: ongoing Phase 1 study CD38 ADC ha
Slide 18: Background on CD38 Target and anti-CD38 mAb STI-1
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved 18 Background on CD38 Target and anti - CD38 mAb STI - 5171 Anti - CD38 mAb A2 Fully human antibody selected from GMAB library Both CD38A2 and Daratumumab have nanomolar affinities for recombinant CD38 protein Exhibits fast - on/fast - off bindi
Slide 19: CD38-ADCs Exert Cytotoxicity against Daratumumab-Resistant MM Tumor Cells
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved CD38 - ADCs Exert Cytotoxicity against Tumor Cells from Daratumamab - Resistant MM Patients 19 Primary MM cells MACS separated and frozen (5x10 e6 cells) Thawed 6 patients CD138+ fractions 4 patient samples could be evaluated Dara samples cultur
Slide 20: From CAR to DAR
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved From CAR to DAR TM scFv Fab TM Chimeric Antigen Receptor (CAR) scFv - based Dimeric Antigen Receptor (DAR) Fab - based linker Hinge Disulfide bond 20
Slide 21: CD38 DAR-T Cells More Potent than CD38 CAR-T at Lower Dose
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved At Lower Dose (4x10e6 Cells), CD38 DAR - T Cells are more Potent than CD38 CAR - T Cells 21
Slide 22: Comparison of DAR-T and CAR-T cGMP Manufacturing Processes
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Illustrative Comparison of DAR - T Cell and CAT - T Cell cGMP Manufacturing Processes Autologous CAR - T Cell Manufacturing Allogeneic DAR - T Cell Manufacturing 22
Slide 23: Evolution of the Platform: From Auto-CAR-T to Allo-DAR-T
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Evolution of the Platform: From Auto - CAR - T to Allo - DAR - T Targeting CD38 Clinical Proof - of - Concept CD38 CAR - T Potential Product KOKI CD38 DAR - T Advantages of DAR - T over CAR - T Chimeric Antigen Receptor (CAR) Dimeric Antigen Rec
Slide 24: STI-6129 ADC Exerts Strong Anti-tumor Activity in Myeloma Mouse Model
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved STI - 6129 ADC Exerts Strong Anti - tumor Activity in Myeloma Mouse Model 24
Slide 25: Seasoned Executive Team
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved 25 Seasoned Executive Team Henry Ji, Ph.D. Chairman, President and Chief Executive Officer Deborah Telman , J.D. SVP and General Counsel Jiong Shao, M.B.A. EVP and Chief Financial Officer Gunnar F. Kaufmann, Ph.D. SVP of Immunotherapy & Head of
Sorrento Therapeutics — Investor Presentation (June 2019) on 6ix